Viatris Inc. logo

Viatris Inc. (MYL)

Market Open
12 Jun, 06:56
XWBO XWBO
14. 16
+0.29
+2.0914%
1.61B Market Cap
6.8 P/E Ratio
0.41% Div Yield
0 Volume
2.95 Eps
13.87
Previous Close
Add Transaction
Day Range
14.03 14.22
Year Range
7.49 14.95
Want to track MYL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

MYL trading today higher at €14.16, an increase of 2.0914% from yesterday's close, completing a monthly increase of 11.2543% or €1.43. Over the past 12 months, MYL stock gained 33.2957%.
MYL pays dividends to its shareholders, with the most recent payment made on May 29, 2026.
The stock of the company had never split.
The company's stock is traded on one exchange.

MYL Chart

People also search for

TLR2
4.36
-0.3429%

Viatris Inc. (MYL) FAQ

What is the stock price today?

The current price is €14.16.

On which exchange is it traded?

Viatris Inc. is listed on XWBO.

What is its stock symbol?

The ticker symbol is MYL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.41%.

What is its market cap?

As of today, the market cap is 1.61B.

Has Viatris Inc. ever had a stock split?

No, there has never been a stock split.

Viatris Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Scott Andrew Smith CEO
XWBO Exchange
- ISIN
US Country
32,000 Employees
- Last Dividend
- Last Split
16 Nov 2020 IPO Date

Overview

Viatris Inc. is a global healthcare company that has marked its presence worldwide since its foundation in 1961, with its headquarters situated in Canonsburg, Pennsylvania. The company operates across various segments globally, including Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. Viatris is committed to providing access to medicines, sustainable operations, and community support, focusing on addressing the needs of patients in both noncommunicable and infectious disease domains. Its wide array of products stretches from prescription brand drugs to complex generics, biosimilars, and active pharmaceutical ingredients (APIs), catering to a broad spectrum of therapeutic areas and underpinning its mission to empower people worldwide to live healthier at every stage of life.

Products and Services

Viatris Inc.'s expansive portfolio encompasses a diverse range of healthcare solutions, from critical medicines to comprehensive support services, aimed at enhancing patient care and access:

  • Prescription Brand Drugs & Generics: Includes essential medications for various health conditions, ensuring patients have access to quality treatment options.
  • Complex Generic Drugs: Offers complex generics that are equivalent to brand-name drugs, providing more accessible and cost-effective treatment alternatives.
  • Biosimilars: The company produces biosimilars for oncology, immunology, endocrinology, ophthalmology, and dermatology, offering high-quality alternatives to existing biologic drugs.
  • Active Pharmaceutical Ingredients (APIs): APIs for a vast range of therapeutic areas including antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors, highlighting the breadth of Viatris’s capabilities in drug manufacturing.
  • Support Services: Beyond just providing medications, Viatris also facilitates diagnostic clinics, educational seminars, and digital tools to help individuals better manage their health, emphasizing the holistic approach to healthcare.

Medications are delivered in various forms, including oral solid doses, injectables, and complex dosage forms, ensuring versatility in administration ways to suit different patient needs. Distribution channels encompass pharmaceutical wholesalers/distributors, retailers, institutional pharmacies, mail-order, e-commerce, and specialty pharmacies, ensuring broad accessibility. Products like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and the EpiPen auto-injector, among others, highlight the wide range and significance of Viatris’s offering in addressing global health issues. Through partnerships, like with Revance Therapeutics, Inc. and Momenta Pharmaceuticals, Inc., Viatris Inc. continues to expand its portfolio, promising innovation and expanded access to essential medicines for patients worldwide.

Contact Information

Address: 1000 Mylan Boulevard
Phone: 724 514 1800